1098 completed. 1098 Phase 1, 335 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1098 | Completed 1098 |
| Phase 2 | 335 | Completed 335 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer BMS-986489 - Small Cell Lung Carcinoma | Phase 1 | Completed | Bristol-Myers Squibb | 10 | 2025-05-07 | 2026-09-24 |
| A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) MK-4700, Pembrolizumab - Malignant Neoplasm | Phase 1 | Completed | Merck Sharp & Dohme LLC | 5 | 2025-04-23 | 2026-03-16 |
| A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer Zirconium Zr 89 crefmirlimab berdoxam, PET/CT Scan - Lung Cancer, Non Small Cell Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 4 | 2025-03-03 | 2026-08-26 |
| A Study of AL8326 in Healthy Subjects 14C-labeled AL8326 - Small Cell Lung Cancer, Solid Tumors | Phase 1 | Completed | Advenchen Laboratories Nanjing Ltd. | 6 | 2025-02-21 | 2025-08-20 |
| A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer LS301-IT - Lung Cancers | Phase 1 | Completed | Integro Theranostics | 24 | 2024-11-07 | 2026-05-19 |
| A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009) Calderasib, Midazolam, Digoxin - Non-small Cell Lung Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 28 | 2024-09-03 | 2026-02-11 |
| A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors sigvotatug vedotin - Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 6 | 2024-08-21 | 2025-12-15 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Amivantamab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 12 | 2024-07-23 | 2026-07-31 |
| TGRX-326 Pharmacokinetic Mass Balance [14C]TGRX-326 - Non Small Cell Lung Cancer | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 6 | 2024-06-26 | 2025-02-21 |
| Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 Diagnostic injection of [123I]I-DARPIN-Ec1, Whole-body planar scintigraphy with [123I]I-DARPIN-Ec1, Whole-body SPECT with [123I]I-DARPIN-Ec1 - Lung Cancer, Ovarian Cancer | Phase 1 | Completed | Tomsk National Research Medical Center of the Russian Academy of Sciences | 10 | 2024-04-14 | 2026-06-24 |
| A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants BAY2927088, Itraconazole, Carbamazepine - Advanced Non-small Cell Lung Cancer, EGFR Mutation | Phase 1 | Completed | Bayer | 30 | 2024-04-10 | 2024-06-20 |
| A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors AMG 355, Pembrolizumab - Advanced Solid Tumors | Phase 1 | Completed | Amgen | 77 | 2024-03-07 | 2026-08-11 |
| TGRX-326 Pharmacokinetic Drug Interaction Itraconazole+TGRX-326, Efavirenz+TGRX-326 - Non Small Cell Lung Cancer | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 34 | 2024-03-04 | 2024-06-27 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1 / Phase 2 | Completed | Immuneering Corporation | 30 | 2024-02-27 | 2025-05-28 |
| A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies AB801, Docetaxel - Advanced Cancer | Phase 1 | Completed | Arcus Biosciences, Inc. | 29 | 2024-01-19 | 2026-10-09 |
| Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer GDC-1971, Osimertinib, Cetuximab - Colorectal Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | Genentech, Inc. | 10 | 2024-01-08 | 2025-11-13 |
| TGRX-326 Pharmacokinetic Food Effect Bioavailability Study cycle 1: treatment drug, cycle 1: reference drug, cycle 1: fasted - Non Small Cell Lung Cancer | Phase 1 | Completed | Shenzhen TargetRx Co., Ltd. | 24 | 2023-12-13 | 2025-05-18 |
| Study of DF6215 in Patients With Advanced Solid Tumors DF6215, pembrolizumab, KEYTRUDA® - Solid Tumor, Adult, Solid Tumor Cancer | Phase 1 | Completed | Dragonfly Therapeutics | 35 | 2023-11-28 | 2026-03-18 |
| Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet - Non-small Cell Lung Cancer | Phase 1 | Completed | BeiGene | 62 | 2023-11-16 | 2026-08-12 |
| A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 RO7496353, Atezolizumab, Capecitabine - Non-small Cell Lung Cancer, Gastric Cancer | Phase 1 | Completed | Genentech, Inc. | 102 | 2023-10-02 | 2026-06-18 |
Showing 20 of 1098. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (781) · Lung Neoplasms (399) · Neoplasms (173) · Breast Neoplasms (172) · Small Cell Lung Carcinoma (166) · Ovarian Neoplasms (142) · Colorectal Neoplasms (137) · Melanoma (130) · Pancreatic Neoplasms (121) · Carcinoma, Renal Cell (102) · Stomach Neoplasms (88) · Squamous Cell Carcinoma of Head and Neck (87) · Head and Neck Neoplasms (86) · Neoplasm Metastasis (83) · Prostatic Neoplasms (78)
Neoplasms by Site (1090) · Respiratory Tract Neoplasms (1083) · Respiratory Tract Diseases (1079) · Lung Diseases (1070) · Neoplasms (925) · Bronchial Neoplasms (867) · Carcinoma, Bronchogenic (866) · Lung Neoplasms (691) · Neoplasms by Histologic Type (419) · Neoplasms, Glandular and Epithelial (349) · Urogenital Diseases (286) · Skin and Connective Tissue Diseases (285) · Digestive System Diseases (284) · Digestive System Neoplasms (282)
Carboplatin (96) · pembrolizumab (83) · Cisplatin (82) · Paclitaxel (78) · Pemetrexed (69) · Erlotinib Hydrochloride (65) · Nivolumab (57) · Radiotherapy (50) · Gemcitabine (48) · Docetaxel (45) · Etoposide (26) · Cetuximab (22) · Bevacizumab (21) · osimertinib (21) · Gefitinib (20)
National Cancer Institute (NCI) (52) · Memorial Sloan Kettering Cancer Center (36) · AstraZeneca (28) · Eli Lilly and Company (25) · M.D. Anderson Cancer Center (22) · Novartis Pharmaceuticals (22) · Pfizer (21) · Bristol-Myers Squibb (15) · AbbVie (14) · Boehringer Ingelheim (14) · Merck Sharp & Dohme LLC (13) · GlaxoSmithKline (12) · Roswell Park Cancer Institute (12) · Bayer (11) · Fuda Cancer Hospital, Guangzhou (10)
United States (791) · Spain (121) · Canada (111) · France (80) · United Kingdom (80) · China (79) · South Korea (77) · Australia (65) · Japan (59) · Netherlands (53) · Taiwan (53) · Germany (51) · Italy (49) · Belgium (47) · Poland (24)
PMID 22473314, PMID 23578144, PMID 24739759, PMID 27863201, PMID 29178442, PMID 29381826, PMID 29748847, PMID 30171779, PMID 31706099, PMID 31996395, PMID 33595690, PMID 34405547, PMID 34408488, PMID 35962934, PMID 39113428, PMID 39462179, PMID 42820295, PMID 11099318, PMID 11410496, PMID 11487589, PMID 11948464, PMID 12056703, PMID 12631594, PMID 15013589, PMID 15033677, PMID 15258838, PMID 15328179, PMID 15667949, PMID 15890573, PMID 16096702, PMID 16170174, PMID 16246975, PMID 16554548, PMID 16730134, PMID 16740761, PMID 16805854, PMID 16990388, PMID 17150016, PMID 17295916, PMID 17336213, PMID 17395581, PMID 17410043, PMID 17869017, PMID 17909358, PMID 18048828, PMID 18090584, PMID 18096059, PMID 18235124, PMID 18245491, PMID 18245546
2016 (30), 2017 (16), 2014 (14), 2015 (13), 2019 (8), 2018 (7), P30CA093373 (7), 2008 (5), 2009 (5), U01CA076576 (5), P30CA033572 (4), P30CA072720 (4), 2023 (3), P30CA006927 (3), P30CA043703 (3)